Table 1 Patients’ clinical characteristics

From: Natural killer cells adopt an activated and decidual-like phenotype after autologous hematopoietic stem cell transplantation in children with cancer

  

n (%)

Gender

Male

8 (61.5%)

Female

5 (38.5%)

Cancer typea

Neuroblastoma

4 (30.8%)

Other tumors

9 (69.2%)

Mobilization regimen

G-CSF

13 (100%)

Conditioning regimen

Busulfan-melphalan

4 (30.8%)

Melphalan

3 (23.1%)

Thiotepa + cyclophosphamide

2 (15.4%)

Other

4 (30.8%)

Second HSCT

Yes

5 (38.5%)

No

8 (61.5%)

Complementary treatment

Radiotherapy

3 (23.1%)

G-CSF

2 (15.4%)

G-CSF ± opioids ± antibiotics

5 (38.5%)

No

3 (23.1%)

Complications after HSCT

Yes

12 (92.3%)

No

1 (7.7%)

Maintenance regimen

Anti-GD2 + cis-retinoic acid

3 (23.1%)

Anti-GD2 + rapamycin

1 (7.7%)

Lenalidomide + bortezomib

1 (7.7%)

No

8 (61.5%)

Relapse

Yes

6b (46.2%)

No

7 (53.8%)

Dead

Yes

3 (23.1%)

No

10 (76.9%)

Median (interquartile range)

Age

 

4 (3–11)

Infused CD34+ cells (×106 cells/kg)

 

5.6 (5.3–6.4)

  1. G-CSF granulocyte colony-stimulating factor.
  2. aCancer types are neuroblastomab and other tumors, including: clear cell renal cell carcinomab, rhabdoid tumorb, paraspinal medulloepithelioma, plasmacytoma, Burkitt’s lymphoma, embryonal tumor with multilayered rosettes, high-grade neuroepithelial tumor with BCOR (BCL6 corepressor) alteration, acute promyelocytic leukemia, and nephroblastoma.
  3. bPatients who have relapsed.
Back to article page